T

The US Oncology Network

Supports independent oncology practices, patient care

Radiation Therapist

Full-TimeUpdated on 10/17/2026Deadline 8/5/27
$49.69 - $85/hr
Entry, Junior, Mid
Bachelor's
Wildomar, CA, USA
In Person
Medical, Clinical & Veterinary

About the job

Requirements
  • Graduate of an accredited radiation therapy technology program.
  • ARRT certification is required.
  • Must hold a valid state license for radiation therapy.
  • Radiation Therapist I requires 0–3 years of experience.
  • Radiation Therapist II requires a minimum of 3 years of experience actively practicing as an RTT.
  • Senior Radiation Therapist requires a minimum of 7 years of experience actively practicing as an RTT.
  • Must be able to sit and use hands to finger, handle, or feel regularly; stand, walk, and reach with hands and arms occasionally; and occasionally lift or move up to 30 pounds.
  • Requires vision and hearing corrected to normal ranges.
Responsibilities
  • Accurately deliver and record radiation therapy treatments under the direction of a radiation oncologist and chief radiation therapist.
  • Accurately enter and maintain patient treatment parameters in the electronic medical record.
  • Participate in clinical instruction of newly hired therapists and students.
  • Assist in maintaining the patient appointment schedule and submitting correct billing information.
  • Accurately cut blocks, when applicable.
  • Accurately make custom molds.
  • Accurately interpret a computerized treatment plan.
  • Maintain a clean, safe, and organized work environment.
Desired Qualifications
  • Halcyon and IX Linac experience is preferred but not required.

About the company

T

The US Oncology Network

View
Website

The US Oncology Network coordinates a nationwide group of independent oncology practices to deliver cancer care close to home. It provides local physicians with clinical and business support, including access to advanced technologies and shared resources, so they can offer comprehensive, value-based treatment in community settings. By pooling expertise and capabilities, the Network helps independent practices operate more efficiently and sustainably while maintaining physician autonomy. Its goal is to improve patient outcomes and physician satisfaction by delivering high-quality, patient-centered care through a scalable, practice-centric platform.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Upper Merion Township, Pennsylvania

Founded

1999

Get referred to The US Oncology Network

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • McKesson said The US Oncology Network added 570 providers in fiscal 2026.
  • Cancer Care Northwest joined in April 2026, expanding Washington and Idaho coverage.
  • Blood Cancer United pilot begins at three-state sites, lifting clinical-trial enrollment.

What critics are saying

  • Omni Healthcare's FCA case against McKesson's US Oncology unit remains active in 2026.
  • McKesson reported $5.66 billion opioid litigation liabilities in June 2026.
  • Cencora's OneOncology acquisition pressures US Oncology's physician recruiting by 2027.

What makes The US Oncology Network unique

  • McKesson-backed network spans 2,500+ providers and 700+ locations nationwide.
  • Its community oncology model keeps cancer care close to home, not academic centers.
  • Sarah Cannon research and 500+ trials give local practices nationwide research access.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Wellness Program
  • Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-6%

2 year growth

-3%
Cancer Center of Kansas
Jul 8th, 2026
19th Annual Mid-America Cancer Symposium.

19th Annual Mid-America Cancer Symposium. Bringing innovation to the Midwest: 19th Annual Mid-America Cancer Symposium returns in 2026. Cancer Center of Kansas (CCK), in collaboration with The US Oncology Network, is proud to announce the return of the 19th Annual Mid-America Cancer Symposium, taking place August 7-8, 2026, in Wichita, Kansas. Building on nearly two decades of excellence, this premier oncology event continues to bring together leading cancer specialists, healthcare professionals, researchers, and industry partners from across the Midwest and beyond The Mid-America Cancer Symposium has become a respected forum for advancing cancer care through education, collaboration, and innovation. Each year, the event provides a unique opportunity for oncology professionals to explore the latest developments in diagnosis, treatment, supportive care, and emerging research that are shaping the future of cancer medicine. This year's program will feature expert-led keynote presentations focused on several important disease areas, including: * Breast Cancer * Genitourinary Cancers * Non-Hodgkin Lymphoma Attendees will gain valuable clinical insights from nationally recognized experts while engaging in meaningful discussions centered on improving outcomes for patients facing cancer. In addition to educational sessions, the symposium will provide extensive networking opportunities, connecting more than 100 cancer care professionals from a variety of disciplines. Participants will also have the opportunity to interact with exhibitors showcasing the latest advancements in oncology therapeutics, technology, diagnostics, and patient care solutions. For Cancer Center of Kansas, the symposium reflects an ongoing commitment to ensuring patients throughout Kansas and the surrounding region benefit from access to the most current knowledge, therapies, and innovations in cancer care. By fostering collaboration among physicians, advanced practice providers, researchers, and industry leaders, CCK continues to strengthen its role as a leader in community-based oncology and hematology care. "Events like the Mid-America Cancer Symposium help bridge the gap between groundbreaking research and real-world patient care," said Dr. Shaker Dakhil, President of Cancer Center of Kansas. "Bringing nationally recognized experts and oncology professionals together in Kansas supports our mission of delivering the highest quality cancer care close to home."(Adapted from prior symposium messaging.) For nearly 20 years, the Mid-America Cancer Symposium has highlighted Wichita and Kansas as a destination for oncology education, innovation, and professional collaboration. CCK is honored to continue hosting this important event and welcoming healthcare leaders dedicated to advancing the fight against cancer. Registration is now open for medical providers, both MDs and APPs. Or, contact Cancer Center of Kansas at [email protected] or 316-262-4467 ext 6184 to inquire further!

Aoncology
Jun 11th, 2026
American Oncology Network appoints Ella Friedman as president, network operations.

American Oncology Network appoints Ella Friedman as president, network operations. June 11, 2026in News FORT MYERS, Fla., June 11, 2026 - American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced the appointment of Ella Friedman as president, network operations. "We are excited to welcome Ella to AON's executive leadership team," said Todd Schonherz, AON's chief executive officer. "Ella brings decades of healthcare leadership experience and a proven track record of driving operational excellence, strategic growth and practice performance. Her deep expertise in oncology and multi-site healthcare operations will be instrumental as we continue expanding access to high-quality, community-based cancer care across the country." Friedman brings more than 25 years of healthcare leadership experience spanning oncology, specialty care and multi-site healthcare operations. In her new role, she will oversee practice operations, strategic growth initiatives, integrations, operational excellence and infrastructure development across AON's national network of physician practices. "I am honored to join AON and contribute to its mission of transforming cancer care in local communities," said Friedman. "Throughout my career, I have been passionate about supporting physicians, strengthening operations and improving the patient experience. I look forward to working alongside AON's talented team to continue delivering exceptional care and advancing the future of community oncology." Prior to joining AON, Friedman served as regional senior vice president and previously senior vice president of operations for The US Oncology Network, where she was responsible for operations management, strategic planning, physician recruitment, marketing and practice growth across multiple states. During her tenure, she held full profit-and-loss responsibility and played a key role in practice integrations, market expansion, operational restructuring and leadership development. She also served as executive director of Rocky Mountain Cancer Centers, one of the nation's largest community oncology practices. "Ella's extensive experience leading complex healthcare organizations and supporting practice growth makes her an outstanding addition to our leadership team," said Stephen "Fred" Divers, MD, AON's chief medical officer. "Her collaborative leadership style and commitment to operational excellence will help strengthen our network and support our mission of delivering patient-centered cancer care close to home." Before entering oncology, Friedman served as senior vice president of business planning and development for Gambro Healthcare, a global leader in renal care services, where she led strategic planning, payer strategy, acquisitions, marketing and growth initiatives. Friedman earned a Bachelor of Arts in biology from Boston University and a Master of Business Administration with concentrations in finance and international business from the Sawyer School of Management at Suffolk University. She also completed the Advanced Management Program in International Business at IESE Business School in Barcelona, Spain. About American Oncology Network. American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON's rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most - providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow American Oncology Network, LLC on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

Oncozine
Oct 16th, 2025
Blood Cancer United(R) and The US Oncology Network to Advance Care in Community Cancer Centers

Blood Cancer United(R) and The US Oncology Network to advance care in community cancer centers. Clinical trials are crucial in the development and testing of new treatment options for patients diagnosed with cancer, determining their safety and efficacy, and establishing a new standard of care. Trials provide data on how novel, investigational drugs work before they are approved by regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. In many instances, clinical trials not only help determine if new treatment approaches are more effective, improving the health-related Quality of Life (hrQoL) of patients and survival oitcomes, investigate if investigational agents have fewer adverse effects or offer a superior treatment compared to the current standard of care; they also explore methods for cancer prevention, test new screening tools, or, using advances in genomic and molecular sequencing, test targeted agents and immunotherapies in specific patient subsets based on biomarkers, or allow researchers to identify which genetic aberrations are most vulnerable to certain drugs. Adaptive clinical trials Traditional clinical trials relied upon a relatively standardized battery of preclinical tests followed by clearly defined and generally understood sequential clinical development steps requiring a large number of patients with extended follow-up to meet discrete predefined regulatory milestones as are necessary for drug approval. Improving Overall Survival Because of the progress made through past clinical trials, survival rates for many cancers have dramatically improved. For example, clinical trials were responsible for raising the survival rate for Hodgkin lymphoma from 15% in 1950 to nearly 90% today. Clinical trials also directly benefit patients participating in them. One reason is that participating patients are generally more closely monitored. This collaborative partnership approach empowers patients to play an active role in their care, while, at the same time, contributing to scientific knowledge, crucial for the ongoing development of novel treatment options. A new collaboration between Blood Cancer United(R)* and The US Oncology Network aims to expand clinical trial education and navigation, helping more patients across the country explore trials as a possible treatment option. Blood Cancer United, the largest global nonprofit dedicated to blood cancer patient support, research, and advocacy, and The US Oncology Network, an organization of independent, community-based providers supported by McKesson, will partner to enhance education about blood cancer clinical trials in select cities, including how to find and access suitable trials. The collaboration will include personalized clinical trial education via Blood Cancer United's Clinical Trial Support Center, as well as clinical trial matching through The US Oncology Network's partnership with Sarah Cannon Research Institute, and patient navigation services to facilitate participation in clinical trials for patients with all types of blood cancer. "We are committed to supporting patients by identifying and removing barriers to clinical trial enrollment," said Gwen Nichols, M.D., Chief Medical Officer of Blood Cancer United. "Collaborations such as this one have great potential to improve patient outcomes directly." A pilot program Blood Cancer United and The US Oncology Network have launched a two-year pilot program at participating sites across three states. Patients at the participating sites will have access to the Clinical Trial Support Center's resources by the end of 2025. "It's incredibly powerful to see our organizations collaborate around a shared goal - strengthening cancer care and access to clinical trials close to home, in communities across the nation," noted Devon Womack, president of The US Oncology Network. "By expanding education around clinical research, we're not just increasing trial enrollment - we're opening doors to new possibilities, empowering patients with more treatment options, and ultimately, offering renewed hope in their fight against cancer," Womack concluded. Note: * Blood Cancer United(R) formerly The Leukemia & Lymphoma Society Clinical trials I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY) - ClinicalTrials.gov ID NCT01042379 Reference [1] Porcher R, Lecocq B, Vray M; participants of Round Table N° 2 de Giens XXVI. Adaptive methods: when and how should they be used in clinical trials? Therapie. 2011 Jul-Aug;66(4):319-26, 309-17. English, French. doi: 10.2515/therapie/2011042. Epub 2011 Aug 19. PMID: 21851793. [2] Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep. 2019 Dec;11(4):303-310. doi: 10.1007/s12609-019-00334-2. Epub 2019 Nov 20. PMID: 33312344; PMCID: PMC7731787. [3] Wang T, Villanueva DJ, Banerjee A, Gifkins D. Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors. Future Sci OA. 2025 Dec;11(1):2458415. doi: 10.1080/20565623.2025.2458415. Epub 2025 Jan 30. PMID: 39885684; PMCID: PMC11792851. [4] Wang T, Banerjee A, Gifkins D. Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies. Future Sci OA. 2025 Dec;11(1):2563483. doi: 10.1080/20565623.2025.2563483. Epub 2025 Sep 22. PMID: 40980857; PMCID: PMC12456206. [5] van der Graaf WTA, Heiss NS, Hynes CL, Keller SP, Weinman A, Blay JY, Franco P, Giles RH, Lacombe D, Schlatter P, Thomas DM, van Waalwijk van Doorn-Khosrovani SB, Williamson M, Plummer R. Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action. Cancer Treat Rev. 2025 Nov;140:103013. doi: 10.1016/j.ctrv.2025.103013. Epub 2025 Aug 14. PMID: 40902364. [6] Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Mar 27;145(13):1369-1381. doi: 10.1182/blood.2023023717. PMID: 40146152; PMCID: PMC11969261. Featured image courtesy (C) 2017 - 2025 Fotolia/Adobe. Used with permission.

StockTitan
Aug 5th, 2025
American Oncology Network Expands Arkansas Presence, Adds Conway Hematology Oncology to National Network

AON's ability to continue attracting established practices demonstrates its value proposition in the community oncology space, potentially strengthening its market position against competitors like US Oncology and OneOncology.

Intelligence360 News
Jun 16th, 2025
The Us Oncology Network To Spend $1,660,000.00 To Occupy 3,197 Square Feet Of Space In Houston Texas.

The US Oncology Network to spend $1,660,000.00 to occupy 3,197 square feet of space in Houston Texas. The US Oncology Network to spend $1,660,000.00 to occupy 3,197 square feet of space in Houston Texas.Houston, Texas — According to state and local development sources, The US Oncology Network plans to invest $1,660,000.00 to build out 3,197 square feet of new space in Houston. The company plans to occupy the new space at 7500 Fannin Street Suite 100a in Houston, on or about February 1, 2026. According to the company website Every day, The US Oncology Network helps over 2,500+ providers deliver value-based, integrated care for patients close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides doctors with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson